|
RPL23AP7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.43929354282591E-15 |
| Normal-vs-Stage2 |
1.61935999999363E-05 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62536650805123E-12 |
| Stage1-vs-Stage2 |
5.242800E-01 |
| Stage1-vs-Stage3 |
2.114400E-02 |
| Stage1-vs-Stage4 |
5.69200000000158E-05 |
| Stage2-vs-Stage3 |
6.706000E-02 |
| Stage2-vs-Stage4 |
4.724600E-03 |
| Stage3-vs-Stage4 |
1.078770E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
3.54959950321643E-10 |
| Normal-vs-Asian |
1.0312994902506E-10 |
| Caucasian-vs-AfricanAmerican |
7.615700E-03 |
| Caucasian-vs-Asian |
2.845000E-01 |
| AfricanAmerican-vs-Asian |
9.748200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.28714833131016E-12 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
8.568400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62558855265615E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
8.59279980502947E-10 |
| Normal-vs-Age(81-100Yrs) |
1.245340E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.734000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.346200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.433000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.994000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.797800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.431000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.220300E-03 |
| Classical-VS-Follicular |
3.220600E-01 |
| Classical-VS-Other |
7.050600E-01 |
| Classical-VS-Normal |
6.18027851118086E-12 |
| Tall-VS-Follicular |
3.477100E-03 |
| Tall-VS-Other |
3.452600E-01 |
| Tall-VS-Normal |
3.06421554796543E-14 |
| Follicular-VS-Other |
8.331600E-01 |
| Follicular-VS-Normal |
2.33600000454359E-08 |
| Other-VS-Normal |
2.028100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.47799566924323E-12 |
| Normal-vs-N1 |
1.07447384323223E-12 |
| N0-vs-N1 |
2.585600E-02 |
|
|
